To Each His Own: a Personalized Vaccine for Metastatic Melanoma

Overview

Journal Gland Surg

Publisher AME Publishing Company

Specialty Endocrinology

Date 2019 Sep 21

PMID 31538056

Citations 2

Authors

Annalisa Chiocchetti

Giuseppe Cappellano

Umberto Dianzani

Affiliations

Soon will be listed here.

Citing Articles

Polypeptides-Based Nanocarriers in Tumor Therapy.

You J, Guo Y, Dong Z Pharmaceutics. 2024; 16(9).

PMID: 39339228 PMC: 11435007. DOI: 10.3390/pharmaceutics16091192.

Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.

Zhou L, Zou M, Xu Y, Lin P, Lei C, Xia X Front Oncol. 2022; 12:864301.

PMID: 35664731 PMC: 9160744. DOI: 10.3389/fonc.2022.864301.

References

Nichols W, Ledwith B, Manam S, Troilo P . Potential DNA vaccine integration into host cell genome. Ann N Y Acad Sci. 1995; 772:30-9. DOI: 10.1111/j.1749-6632.1995.tb44729.x. View

Hawkins R, Zhu D, Ovecka M, Winter G, Hamblin T, Long A . Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood. 1994; 83(11):3279-88. View

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

Achkar T, Tarhini A . The use of immunotherapy in the treatment of melanoma. J Hematol Oncol. 2017; 10(1):88. PMC: 5402170. DOI: 10.1186/s13045-017-0458-3. View

Ott P, Hu Z, Keskin D, Shukla S, Sun J, Bozym D . An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662):217-221. PMC: 5577644. DOI: 10.1038/nature22991. View

Schlake T, Thess A, Fotin-Mleczek M, Kallen K . Developing mRNA-vaccine technologies. RNA Biol. 2012; 9(11):1319-30. PMC: 3597572. DOI: 10.4161/rna.22269. View

Krummel M, Allison J . CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995; 182(2):459-65. PMC: 2192127. DOI: 10.1084/jem.182.2.459. View

Hodis E, Watson I, Kryukov G, Arold S, Imielinski M, Theurillat J . A landscape of driver mutations in melanoma. Cell. 2012; 150(2):251-63. PMC: 3600117. DOI: 10.1016/j.cell.2012.06.024. View

Dianzani C, Minelli R, Gigliotti C, Occhipinti S, Giovarelli M, Conti L . B7h triggering inhibits the migration of tumor cell lines. J Immunol. 2014; 192(10):4921-31. DOI: 10.4049/jimmunol.1300587. View

10.

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

11.

Siegel R, Miller K, Jemal A . Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7-30. DOI: 10.3322/caac.21387. View

12.

Leiter U, Meier F, Schittek B, Garbe C . The natural course of cutaneous melanoma. J Surg Oncol. 2004; 86(4):172-8. DOI: 10.1002/jso.20079. View

13.

Dianzani C, Minelli R, Mesturini R, Chiocchetti A, Barrera G, Boscolo S . B7h triggering inhibits umbilical vascular endothelial cell adhesiveness to tumor cell lines and polymorphonuclear cells. J Immunol. 2010; 185(7):3970-9. DOI: 10.4049/jimmunol.0903269. View

14.

Lipson E, Sharfman W, Chen S, McMiller T, Pritchard T, Salas J . Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med. 2015; 13:214. PMC: 4491237. DOI: 10.1186/s12967-015-0572-3. View

15.

Redoglia V, Dianzani U, Rojo J, Portoles P, Bragardo M, Wolff H . Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor. Eur J Immunol. 1996; 26(11):2781-9. DOI: 10.1002/eji.1830261134. View

16.

Gonzalez F, Gleisner A, Falcon-Beas F, Osorio F, Lopez M, Salazar-Onfray F . Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother. 2015; 10(11):3261-9. PMC: 4514089. DOI: 10.4161/21645515.2014.982996. View

17.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

18.

Callahan M, Postow M, Wolchok J . CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. Front Oncol. 2015; 4:385. PMC: 4295550. DOI: 10.3389/fonc.2014.00385. View

19.

Sahin U, Derhovanessian E, Miller M, Kloke B, Simon P, Lower M . Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547(7662):222-226. DOI: 10.1038/nature23003. View